SeraNovo (Leiden, The Netherlands) has announced the closing of a multi-compound deal with AstraZeneca (Cambridge, United Kingdom).
Niall Hodgins, Chief Executive Officer of SeraNovo commented: “SeraNovo has grown substantially in recent years in terms of our technical capabilities and worldwide customer base. It is great to be able to share news of one of our most important collaborations with such a historic company. Our technology will again be used to drive important therapies to patients. We look forward to a long and prosperous relationship with AstraZeneca.”
We look forward to a long and prosperous relationship
SeraNovo is a formulation technology provider that enhances the bioavailability of poorly soluble Active Pharmaceutical Ingredients (APIs). The team specialises in addressing two core issues with our proprietary technology: enhancing bioavailability and reducing development time to the clinic. As the inventor of this technology, SeraNovo owns the associated know-how and intellectual property.
